Pharmacological inhibition of SPP1 in vivo significantly increases the weight of the gastrocnemius and tibialis anterior muscles, improves the atrophy phenotype, and reprograms the muscle transcriptome, thereby confirming SPP1 as the central pathogenic factor and therapeutic target in the CKD-muscle axis (70). This evidence concerns the gene SPP1 and chronic kidney disease.